Javascript must be enabled to continue!
Abstract 1475: FOXO transcription factors regulate WNT pathway gene expression in GBM
View through CrossRef
Abstract
Basal-like breast cancer (BBC) and Glioblastoma Multiforme (GBM) are aggressive cancers associated with poor prognosis. BBC and GBM express stem gene expression signatures which are in part driven by FOXO transcription factors. To gain further insight into the impact of FOXO1 in BBC, we treated BT549 cells with the FOXO1 inhibitor AS1842856 and performed RNA Seq. Gene Set Enrichment Analysis (GSEA) with RNA Seq. data indicated that a set of WNT target genes including LEF1 and AXIN2 were robustly induced after 48-hours of AS1842856 treatment. These same genes were also induced in GBM cell lines U87MG, LN18, LN229, A172, and DBTRG upon AS1842856 treatment. RNAi targeting of FOXO1 led to reduced LEF1 gene expression in BT549 and U87MG cells at 18-hour and 24-hour timepoints respectively. CRISPR Cas9-mediated FOXO1 disruption led to reduced expression of canonical WNT target gene LEF1 in U87MG cells.
Citation Format: Megan Keniry, Shania Pintor, Alma Lopez, David Flores. FOXO transcription factors regulate WNT pathway gene expression in GBM [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1475.
American Association for Cancer Research (AACR)
Title: Abstract 1475: FOXO transcription factors regulate WNT pathway gene expression in GBM
Description:
Abstract
Basal-like breast cancer (BBC) and Glioblastoma Multiforme (GBM) are aggressive cancers associated with poor prognosis.
BBC and GBM express stem gene expression signatures which are in part driven by FOXO transcription factors.
To gain further insight into the impact of FOXO1 in BBC, we treated BT549 cells with the FOXO1 inhibitor AS1842856 and performed RNA Seq.
Gene Set Enrichment Analysis (GSEA) with RNA Seq.
data indicated that a set of WNT target genes including LEF1 and AXIN2 were robustly induced after 48-hours of AS1842856 treatment.
These same genes were also induced in GBM cell lines U87MG, LN18, LN229, A172, and DBTRG upon AS1842856 treatment.
RNAi targeting of FOXO1 led to reduced LEF1 gene expression in BT549 and U87MG cells at 18-hour and 24-hour timepoints respectively.
CRISPR Cas9-mediated FOXO1 disruption led to reduced expression of canonical WNT target gene LEF1 in U87MG cells.
Citation Format: Megan Keniry, Shania Pintor, Alma Lopez, David Flores.
FOXO transcription factors regulate WNT pathway gene expression in GBM [abstract].
In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL.
Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1475.
Related Results
Abstract 1249: SetD2 histone methyltransferase mutation status predicts treatment response in glioblastoma: Strategies to overcome chemoresistance
Abstract 1249: SetD2 histone methyltransferase mutation status predicts treatment response in glioblastoma: Strategies to overcome chemoresistance
Abstract
Purpose: Glioblastoma (GBM) is a highly aggressive primary brain tumor. A major challenge in GBM treatment is tumor resistance to radiation and chemotherapy...
WNT Receptor Requirements for Dishevelled Phosphorylation
WNT Receptor Requirements for Dishevelled Phosphorylation
The Dishevelled (DVL) protein is a key component of WNT signaling that relays signals from receptors to downstream effectors. It has been shown that following WNT ligand binding to...
Abstract 1584: Wnt/beta-catenin and Foxa2 axis activates AR signaling in castration resistant prostate cancer
Abstract 1584: Wnt/beta-catenin and Foxa2 axis activates AR signaling in castration resistant prostate cancer
Abstract
Background: Prostate cancer (PCa) is the leading cancer among men in the world. Androgen deprivation therapy is a common treatment to cease prostate growth....
Abstract 1260: Tumor hypoxia conditions glioblastoma cells for immunosuppression
Abstract 1260: Tumor hypoxia conditions glioblastoma cells for immunosuppression
Abstract
Glioblastoma (GBM) is the most common and lethal malignant brain tumor that invariably recurs after standard therapy, with a median survival of only ~16 mon...
WNT Signaling Pathway and Stem Cell Signaling Network
WNT Signaling Pathway and Stem Cell Signaling Network
Abstract
WNT signals are transduced to the canonical pathway for cell fate determination, and to the noncanonical pathway for control of cell movement and tissue pol...
Abstract 1794: Cross-regulation of polycomb group protein BMI1 and WNT inhibitors.
Abstract 1794: Cross-regulation of polycomb group protein BMI1 and WNT inhibitors.
Abstract
Polycomb group (PcG) proteins are evolutionarily conserved gene silencers, which determine cell fate decisions during development. These proteins are often ...
Role of Wnt Signaling in Colon Cancer Cell Metabolism
Role of Wnt Signaling in Colon Cancer Cell Metabolism
Over eighty percent of colon cancers derive from mutations that overactivate the Wnt pathway and cause cell transformation. These mutations stabilize β‐catenin protein, leading to ...
ZBTB7A suppresses glioblastoma tumorigenesis through the transcriptional repression of EPB41L5
ZBTB7A suppresses glioblastoma tumorigenesis through the transcriptional repression of EPB41L5
Abstract
Glioblastoma multiforme (GBM), the most aggressive and malignant glioma, has poor prognosis. Although patients with GBM are treated with surgery, chemotherapy, and...

